This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DaVita Clinical Research Celebrates Milestone Year

DaVita Clinical Research ® (DCR ®), a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, today released a recap of its milestone year in 2012.

“DaVita Clinical Research experienced a very strong year in 2012,” said Dr. Mahesh Krishnan, vice president of DaVita Clinical Research. “From expanding our research capabilities to producing innovative studies with results to drive better clinical outcomes, we’re making strides to improve the quality of life for chronic kidney disease and end-stage renal disease patients around the world.”

Major initiatives and highlights for DCR in 2012 include:

New research facility opened in Colorado – The new facility encompasses 35,000 square feet and is physically connected to St. Anthony Hospital in Lakewood, Colo. The 80-bed facility brought more than 50 specialized research jobs to the area and increased DCR’s physical capacity from 42 to 122 beds in North America, including the existing facility in Minnesota. The facility supports high-risk studies and has expanded ability to support both patient and healthy volunteer Phase I clinical studies.

DCR hired four key individuals to ignite the expansion at its latest clinical research facility. The new team members are Dr. Christopher Galloway, medical director; Chad Jaeger, vice president of Clinical Operations; Amy Denvir, director of Operations - Denver; and Michael Kreuter, director of Data Management.

Through this investment, DCR will continue to explore opportunities to both expand its patient-driven leadership position and diversify its ability to conduct critical research in healthy normal volunteers.

Innovative clinical research programs highlighted at industry meetings – Researchers from DCR and DaVita®, the dialysis division of DaVita HealthCare Partners Inc., presented results from a number of innovative clinical improvement programs and health economic studies originating from DaVita and its research partners. The findings were shared at three premier health care meetings in 2012: The National Kidney Foundation Spring Clinical Meeting, the 17 th Annual International Society for Pharmacoeconomics and Outcomes Research International Meeting, and the American Society of Nephrology’s Kidney Week.

DCR provides a collaborative bridge between DaVita services and the pharmaceutical and biotech research community; DCR also shares DaVita’s dedication to improving the health and well-being of kidney patients.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs